Press Releases

Date Title and Summary Additional Formats
Toggle Summary Radius Initiates Phase 2a Clinical Trial of RAD1901 in Menopausal Hot Flashes View HTML
Toggle Summary Radius' Investigational Bone Anabolic Agent, BA058, Increased Bone Mineral Density (BMD) at Key Fracture Sites in Phase 2 Clinical Trial in Postmenopausal Osteoporosis View HTML
Toggle Summary Radius Presents Positive Phase 2a Study Results Establishing Clinical Proof of Concept for RAD1901 in Reducing Menopausal Hot Flashes View HTML
Toggle Summary Radius Announces Closing of $91 Million Financing to Advance BA058 Injection into Phase 3 Osteoporosis Study View HTML
Toggle Summary Radius, 3M Drug Delivery Systems Sign Development Agreement for Transdermal Delivery of BA058 for Treatment of Osteoporosis View HTML
Toggle Summary Radius Closes $27.65 Million Second Tranche of Previously Announced Financing View HTML
Toggle Summary Radius Transitions Company Leadership; Names Michael Wyzga President and Chief Executive Officer to Advance Phase 3 Osteoporosis Drug and Drive Corporate Strategy
Radius Transitions Company Leadership; Names Michael Wyzga President and Chief Executive Officer to Advance Phase 3 Osteoporosis Drug and Drive Corporate Strategy CAMBRIDGE, MA--(Marketwire - Dec 5, 2011) - C. Richard Lyttle retires as President and CEO and will serve as interim CSO Kurt Graves
View HTML
Toggle Summary Radius Closes $21.4 Million Third and Final Equity Tranche of Previously Announced Financing
Radius Closes $21.4 Million Third and Final Equity Tranche of Previously Announced Financing CAMBRIDGE, MA--(Marketwire - Dec 16, 2011) - Radius Health, Inc. ("Radius") announced today the closing of the third and final equity tranche of the company's $91 million financing round announced in May
View HTML
Toggle Summary Radius Announces Topline Results of Successful Phase 1b Clinical Trial of BA058 Microneedle Patch for the Transdermal Treatment of Osteoporosis
Technical Feasibility Demonstrated for Transdermal Delivery of BA058; Study Endpoints of Pharmacokinetic Profile, Safety, and Tolerability Successfully Met; Results Support Plan for Future Phase 2 Proof-of-Concept Clinical Trial
View HTML
Toggle Summary Radius Health, Inc. Files Registration Statement for Proposed Public Offering
Radius Health, Inc. Files Registration Statement for Proposed Public Offering CAMBRIDGE, MA--(Marketwire - Feb 7, 2012) - Radius Health, Inc., a biopharmaceutical company focused on developing new therapeutics for the treatment of osteoporosis and other women's health conditions, today announced
View HTML